Lupus最新文献

{"title":"Trends of preemptive kidney transplantation in lupus compared to other primary diseases leading to end stage kidney disease in the United States of America.","authors":"Gabriel Contreras, Javier Pagan, Tali Elfassy, Miguel Bandes, Nicolas Bustamante, Mariella Ortigosa-Goggins, Laura Aponte Becerra, Jair Munoz Mendoza, Yelena Drexler, Shawn Alonso, David Roth","doi":"10.1177/09612033251344189","DOIUrl":"10.1177/09612033251344189","url":null,"abstract":"<p><p>PurposeThe proportion of lupus patients with end-stage kidney disease (ESKD) undergoing preemptive kidney transplantation (PKT) is <5%, due to concern for poor outcomes. In this study, we estimate trends and the likelihood of PKT in lupus patients compared to non-lupus patients approaching ESKD. Additionally, we compare kidney allograft failure (KAF) and all-cause mortality in lupus and non-lupus recipients of PKT.MethodsWe included 33,415 lupus and 3,001,746 non-lupus incident ESKD patients from the United States Renal Data System (USRDS). Patients were stratified in 6 groups: lupus, polycystic kidney disease (PKD), other glomerular diseases (GD), diabetes (DM), hypertension (HTN), and other diseases (OD). Trends of PKT were assessed with Cochran-Armitage tests. KAF and mortality were compared stratifying by primary diagnosis leading to ESKD.FindingsPKT trends increased in the lupus (3.02% to 4.65%, <i>p</i> = 0.001), PKD (3.14% to 16.71%, <i>p</i> < 0.001), and GD (3.94% to 5.90%, <i>p</i> < 0.001) groups, but decreased in the DM (2.11% to 0.71%, <i>p</i> < 0.001), HTN (1.15% to 0.92%, <i>p</i> < 0.001) and OD (3.89% to 3.60%, <i>p</i> < 0.001) groups. KAF rate (per 100 patient-years) was similarly low in lupus (4.40), PKD (2.47), GD (4.28) and OD (4.84) recipients, and similarly high in DM (6.24) and HTN (7.42) recipients. Lupus compared to DM recipients of PKT had significantly lower risk of KAF in adjusted Cox models (Hazard Ratio [95% CI] 0.85 [0.76 to 0.95]). Mortality rate was similarly low in lupus (2.59), PKD (2.20), GD (2.62) and OD (2.99) recipients, and similarly high in HTN (6.39) and DM (6.49) recipients. Lupus compared to DM recipients of PKT had significantly lower risk of all-cause mortality in adjusted models (0.56 [0.50 to 0.64]).ConclusionPKT trends increased from 1985 to 2019 in patients with lupus, PKD and GD. PKT patients with lupus have lower risk of KAF and mortality compared to patients with DM.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"775-786"},"PeriodicalIF":1.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144102217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commonalities between thyroid disease and systemic lupus erythematosus (SLE).","authors":"Lin-Lin Li, Qiu-Rui Li, Lu Li, Hui-Xia Cao, Feng-Min Shao","doi":"10.1177/09612033251345193","DOIUrl":"10.1177/09612033251345193","url":null,"abstract":"<p><p>Systemic lupus erythematosus (SLE) is characterized by multiple organ involvements. One notable manifestation of SLE is thyroid disease, which has been documented in various studies with significant variability in prevalence and presentation. Observational studies have indicated that thyroid dysfunction, particularly autoimmune thyroid disease (AITD) characterized by hypothyroidism, is commonly associated with SLE. Despite these observation, the exact relationship between SLE and thyroid disease still remain poorly understood. Several factors may contribute to the pathogenesis of SLE companied with AITD, including genetic susceptibility, environmental influences, pharmacological agents, infections and immune system dysregulation. In light of these considerations, we conducted a review of the literature to observe the associations and potential mechanisms linking thyroid disease to SLE. This review aims to shed light on the complexities of these interrelated conditions and provide insights into their co-occurrence.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"767-774"},"PeriodicalIF":1.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144120220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validity and reliability of the Japanese version of LupusQoL: Assessment of disease-specific health-related quality of life in systemic lupus erythematosus.","authors":"Sayuri Yamashita, Yasuhiro Katsumata, Sayumi Baba, Yuko Okamoto, Naoko Konda, Masayoshi Harigai","doi":"10.1177/09612033251344995","DOIUrl":"10.1177/09612033251344995","url":null,"abstract":"<p><p>ObjectiveTo develop a Japanese version of LupusQoL (LupusQoL-JP) and assess its validity and reliability in patients with systemic lupus erythematosus (SLE).MethodsThis study consisted of two independent cross-sectional analyses using data from two different periods at our university clinic: 2011 (initial period, <i>n</i> = 266) and 2015-2018 (second period, <i>n</i> = 133). The English version of the LupusQoL was translated into Japanese and administered to Japanese patients with SLE, alongside other questionnaires, including the Medical Outcomes Study Short Form-36 (SF-36) and the 5-level EuroQoL 5-Dimensions Questionnaire (EQ-5D-5L). Physicians also completed measures such as the Systemic Lupus International Collaborating Clinics/American College of Rheumatology (ACR) Damage Index (SDI) and SLE Disease Activity Index 2000 (SLEDAI-2K), and assessed lupus low disease activity state (LLDAS) attainment.ResultsLupusQoL-JP showed acceptable internal consistency (Cronbach's α > 0.8). All subscales, except for fatigue, demonstrated good test-retest reliability. The LupusQoL-JP and SF-36 scores were strongly correlated with comparable domains. The LupusQoL-JP subscale scores were moderately to strongly correlated with the EQ-5D-5L index values, while weakly correlated with the SDI and generally not correlated with age, disease duration, prednisolone dosage, or SLEDAI-2K. Some LupusQoL-JP domains were able to differentiate between the LLDAS and non-LLDAS groups.ConclusionLupusQoL-JP was successfully translated, adapted, and validated. It demonstrated good concurrent validity with comparable domains of the SF-36 and was independent of SLEDAI-2K. Patients with SLE in LLDAS were partly associated with better disease-specific health-related quality of life, as assessed by LupusQoL-JP.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"810-818"},"PeriodicalIF":1.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144094223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The hidden costs of lupus erythematosus: Comment on \"healthcare costs of systemic lupus erythematosus in New Zealand\".","authors":"Claudine Howard-James, Bairbre Wynne","doi":"10.1177/09612033251344989","DOIUrl":"10.1177/09612033251344989","url":null,"abstract":"","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"874-875"},"PeriodicalIF":1.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144102195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence, clinical features, and possible associated factors of mesenteric vasculitis occurrence in patients with systemic lupus erythematosus: An age-, year-at SLE diagnosis, and disease duration-controlled study.","authors":"Wanitcha Gumtorntip, Piyanut Thanunchai, Amonlaya Amantakul, Suwalee Pojchamarnwiputh, Nuntana Kasitanon, Worawit Louthrenoo","doi":"10.1177/09612033251344154","DOIUrl":"10.1177/09612033251344154","url":null,"abstract":"<p><p>ObjectivesStudies on associated or risk factors of lupus mesenteric vasculitis (LMV) in patients with systemic lupus erythematosus (SLE) are limited. This study aimed to determine the prevalence, clinical features, treatment, and outcomes of LMV in Thai SLE patients, and to identify potential factors that predispose to its occurrence.MethodsSLE patients with LMV were identified in a lupus cohort. Controls were matched to cases by age-, year-at SLE diagnosis, and disease duration (cases:controls = 1:2).ResultsOf 1538 patients in the cohort, 34 (2.2%) had 42 LMV episodes, but 39 episodes from 31 patients had adequate data for analysis. Nausea, vomiting and diarrhea were noted in 61.5%-69.2%. All of the patients had abdominal pain (diffuse in 64.1%), and 12.8%-15.4% had signs of peritoneal irritation. Small bowel and colon were common sites involved. All episodes responded well to corticosteroids and immunosuppressive drugs. When compared to the controls, at LMV onset, LMV patients had more active disease in renal, mucocutaneous and hematologic systems. They had a higher degree of proteinuria, and SLE disease activity (mSLEDAI-2K score). At 3 months prior to LMV onset, the LMV group was more anemic and had higher proteinuria. The LMV patients received less prednisolone and fewer immunosuppressive drugs at LMV onset, and fewer immunosuppressive drugs at 3 months prior to it. They received a higher daily dose of prednisolone in both periods.ConclusionLMV is a rare manifestation in SLE. Active disease, particularly in the renal and hematologic systems, was common prior to LMV onset.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"787-798"},"PeriodicalIF":1.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of peritubular capillaritis in severity of lupus nephritis.","authors":"Emel Yaldır, Balça Begüm Cengiz, Mustafa Fuat Açıkalın, Nazife Şule Yaşar Bilge","doi":"10.1177/09612033251335821","DOIUrl":"10.1177/09612033251335821","url":null,"abstract":"<p><p>Background & ObjectivePresence of lupus nephritis is associated with a shorter time to death in systemic lupus erythematosus. The aim of this study was to determine the frequency of peritubular capillaritis (ptc) and its relationship with both active and chronic lesions in lupus nephritis.Material-MethodsSpecimens from 57 patients were re-evaluated. The degree of inflammation within the peritubular capillaries in each biopsy was assessed according to the Banff classification, and ptc scoring was performed. Additionally, patients were grouped based on high/low activity and chronicity index scores.ResultsForty-five (78.9%) of the patients were female, with a mean age of 27.43 years. Ptc was identified in 45 (78.9%) patients, with ptc scores of 1, 2, and 3 observed in 20 (35.08%), 20 (35.08%), and 5 (8.7%) patients, respectively. Severe ptc (scores 2 or 3) was more commonly detected in patients with elevated serum creatinine (>1.20 mg/dL) compared to those with normal creatinine levels (92.3% vs 29.5%, <i>p</i> < 0.001). The severity of ptc was higher in Class 4 patients than in Class 3 patients (68.2% vs 21.7%, <i>p</i> = 0.005). The rate of high ptc scores was greater in patients with an activity index of 6 or above compared to those with an activity index below 6 (62.5% vs 30.3%, <i>p</i> = 0.032). No significant correlation was found between the chronicity index and ptc.ConclusionsThe findings of this study suggest that ptc is a frequently observed pathological feature in patients with lupus nephritis. Furthermore, the severity of ptc appears to be positively associated with elevated serum creatinine levels, and higher ptc scores are more commonly detected in cases with a high activity index.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"742-750"},"PeriodicalIF":1.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12123054/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144003077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progressive repigmentation of hypopigmented lesions in discoid lupus erythematosus with anifrolumab: A report of two cases.","authors":"Margot Hulin, Agathe Le Seac'h, Léa Jaume, Julien Seneschal, Katia Boniface, Annick Barbaud, Alexis Mathian, Zahir Amoura, François Chasset","doi":"10.1177/09612033251345017","DOIUrl":"10.1177/09612033251345017","url":null,"abstract":"<p><p>We report two cases of patients with refractory discoid lupus erythematosus (DLE) and dark skin phototypes who experienced progressive perifollicular repigmentation of depigmented lesions under anifrolumab therapy, with sustained improvement over 18 months. These observations highlight a potential novel effect of anifrolumab on cicatricial dyspigmentation in DLE. This effect may represent a valuable therapeutic option for DLE-related damage, particularly in patients with darker skin types.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"761-763"},"PeriodicalIF":1.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical significance of anti-lipoprotein lipase antibodies in Japanese patients with systemic lupus erythematosus.","authors":"Taro Horino, Takeshi Kashio, Satoshi Inotani, Yoshio Terada","doi":"10.1177/09612033251344051","DOIUrl":"10.1177/09612033251344051","url":null,"abstract":"<p><p>ObjectivesAs there is a lack of reports on the association between anti-lipoprotein lipase (anti-LPL) antibodies and dyslipoproteinemia, we aimed to analyse the association between anti-LPL antibodies and the clinical and serological characteristics of patients with systemic lupus erythematosus (SLE) and cardiovascular (CV) events.MethodsEighty patients with SLE were examined for the presence of anti-LPL antibodies via western blotting. Data on laboratory findings and the occurrence of CV events were retrospectively collected and evaluated. Patients with SLE were classified into two groups according to the detection of anti-LPL antibodies: anti-LPL antibody-positive and antibody-negative.ResultsAnti-LPL antibody immunoglobulin G was detected in 28 patients with SLE (35.0%). Additionally, triglyceride levels tended to be higher in the anti-LPL antibody-positive group than in the anti-LPL antibody-negative group. The former exhibited significantly higher levels of serum albumin, anti-Smith antibody, and IgM than the latter. The incidence of CV events was higher in the anti-LPL antibody-positive group than in the anti-LPL antibody-negative group (35.7% vs 5.8%, <i>p</i> = .001). Additionally, the risk of CV events was significantly higher in the anti-LPL antibody-positive group, with a hazard ratio of 169.20 (95% confidence interval: 5.75-4981.54, <i>p</i> = .003).ConclusionIn this study, the positivity rate of anti-LPL antibodies was high among Japanese patients with SLE. Additionally, a significantly higher incidence of CV events was observed in the anti-LPL antibody-positive group compared to that in the anti-LPL antibody-negative group.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"699-704"},"PeriodicalIF":1.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chorea associated with systemic lupus erythematosus- a systematic review.","authors":"Paulo Rogério Julio, Carla Helena Capello, Jaqueline Cristina de Amorim, Samuel de Oliveira Andrade, Laura Silveira-Moriyama, Ana Carolina Coan, Simone Appenzeller","doi":"10.1177/09612033251344045","DOIUrl":"10.1177/09612033251344045","url":null,"abstract":"<p><p>ObjectiveChorea is one of the 19 neuropsychiatric manifestations observed in systemic lupus erythematosus (SLE). This article reviews the literature to determine the prevalence and clinical and laboratory features associated with chorea in SLE.MethodsWe performed a literature review following the PRISMA guidelines and using the following MESH terms in the search and analysis: \"Chorea\", \"movement disorders\", \"systemic lupus erythematosus\", \"SLE\", \"neuropsychiatric manifestations\", \"neuropsychiatric lupus (NPSLE)\", with full articles in English, Portuguese, and Spanish, between September 1999 and January 2024, in PubMed and Scielo.Results13,922 patients from 60 cohort studies and 41 patients from 18 case/series reports were included. Chorea had a pooled prevalence of 1.1% in SLE patients. We found no association between chorea and clinical or immunological features reported in cohort studies. In case series and case reports, chorea occurred more frequently before or at SLE diagnosis and more frequently in childhood-onset SLE. We propose an investigation and treatment scheme based on the literature review.ConclusionChorea is a rare manifestation in SLE and factors associated with its occurrence have not been addressed in cohort studies.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"687-698"},"PeriodicalIF":1.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144102190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baby you can drive my CAR-T cells.","authors":"Daniela Garelick, David A Isenberg","doi":"10.1177/09612033251335798","DOIUrl":"10.1177/09612033251335798","url":null,"abstract":"<p><p>ObjectiveTo evaluate the potential of chimeric antigen receptor T-cell (CAR-T) therapy in revolutionizing the treatment of systemic lupus erythematosus (SLE) and to outline necessary future steps for its implementation.MethodsA careful literature search was conducted for relevant English language papers on pubmed.ResultsPreliminary data suggest that CAR-T therapy could significantly improve SLE outcomes. Demonstrating remarkable clinical and serologic improvements in SLE patients, with all treated patients achieving remission and discontinuing conventional steroids and immunosuppressive drugs. To realize this potential, it is imperative to advance our understanding and application of CAR-T therapy. Rigorous research is necessary to validate current findings, and clinical trials must be conducted to assess both the short- and long-term efficacy and safety across diverse populations. Identifying appropriate patient populations is crucial, as CAR-T may also address compliance issues. Despite its current high cost, the financial burden is comparable to the long-term costs of severe SLE treatment. Strategies to reduce costs, including production efficiencies and outpatient treatment options, are under exploration. Early intervention could enhance its feasibility and impact on long-term prognosis.ConclusionCAR-T therapy holds promise for altering the prognosis of SLE and potentially offering a cure. However, substantial efforts are required to validate its efficacy, ensure safety, identify suitable patient cohorts, and reduce financial barriers. This development represents an exciting advancement in SLE treatment, necessitating urgent and focused research and clinical application.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"653-656"},"PeriodicalIF":1.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12123052/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144017650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}